Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2012 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (391)	12/11/2012 12:51:46 PM
From: Guy	2 Recommendations Read Replies (1) \| Respond to of 513

Thanks for running this contest BulbaMan. By the way, do you plan on running a contest in 2013?

To: BulbaMan who wrote (391)	12/14/2012 6:00:57 PM
From: BulbaMan	Read Replies (1) \| Respond to of 513

12/14/12 Contest Update The week ended with the FDA’s surprise early approval of Ariad’s ponatinib. This was terrific news for patients but ARIA’s stock took a dive, apparently because the FDA black box warning label was scarier than expected. ARIA was the second most popular Contest portfolio stock pick (being in 13 portfolios, with only MNTA in 14 more popular), yet the Contest median still managed to have an excellent week. At Friday’s close, the Contest median was up 27.16% YTD (vs. up 23.89% YTD a week ago). In comparison, the Nasdaq Biotech Index was up 32.83% YTD (vs. up 31.70% YTD a week ago), while the Nasdaq Composite Index was up 14.06% YTD (vs. up 14.31% YTD a week ago). Contest leader GENE’s portfolio, up 164.49% YTD, had another sizzling week, widening its lead over No. 2 RKRW’s portfolio, up 134.39% YTD. BIOMAV’s portfolio, up 58.22% YTD, was hurt by ARIA’s drop but still managed to hold on to third place by a smidgen. At Friday's close, 6 of the 38 Contest portfolios were still in the red, with 15 of the 38 portfolios beating the NBI. Below is the Top Ten list. Also below are the Top 5 & Worst 5 Stocks ranked by % Gained and % Lost for the week. (Foreign stock prices are not converted to US$ in the weekly and YTD Top 5 & Worst 5 tables, when posted.) Portfolio adjustments: Symbol change with NEO replacing NGNM. My heart goes out to the families of the children and teachers slaughtered in Connecticut. Hopefully, this will be a weekend of reflection on what we can do to prevent such tragedies in the future. (All corrections, especially adjustments for splits, greatly appreciated.) P.S. I’d still appreciate feedback on my proposed change of the Contest end date to Monday, 12/31. See my prior post on the change here: Message 28599540 12/14/12 Rank Name Profit/Loss 1 GENE 164,492 2 RKRW 134,387 3 BIOMAV 58,220 4 PGO 58,005 5 TNSAF 55,177 6 BULBA 52,395 7 DOUGH 51,590 8 BIOJIM 48,389 9 ANON 44,547 10 DONS 43,976 Week's Top 5 Gainers Symbol 12/7 12/14 Wk.%chg. CRME 0.26 0.50 95.31% YMI 1.62 2.88 77.78% GERN 1.06 1.53 44.34% ISR 0.50 0.66 32.03% CLDX 5.52 6.70 21.38% Week's Worst 5 Losers Symbol 12/7 12/14 Wk.%chg. ZGNX 2.36 1.21 -48.73% RIGL 8.19 6.52 -20.39% PYMX 0.20 0.17 -15.00% RGDX 1.60 1.36 -15.00% ARIA 22.07 18.93 -14.22%